105 related articles for article (PubMed ID: 8211583)
1. Infection prevention in patients with severe multiple trauma with the immunomodulator beta 1-3 polyglucose (glucan).
de Felippe Júnior J; da Rocha e Silva Júnior M; Maciel FM; Soares Ade M; Mendes NF
Surg Gynecol Obstet; 1993 Oct; 177(4):383-8. PubMed ID: 8211583
[TBL] [Abstract][Full Text] [Related]
2. Endotoxemia is masked in fungal infection due to enhanced endotoxin clearance by beta-glucan.
Yokota M; Tsujinaka T; Kambayashi J; Watase M; Sakon M; Mori T
Int Surg; 1991; 76(4):255-60. PubMed ID: 1778725
[TBL] [Abstract][Full Text] [Related]
3. Beneficial effect of enhanced macrophage function in the trauma patient.
Browder W; Williams D; Pretus H; Olivero G; Enrichens F; Mao P; Franchello A
Ann Surg; 1990 May; 211(5):605-12; discussion 612-3. PubMed ID: 2111126
[TBL] [Abstract][Full Text] [Related]
4. Application of beta-1,3-glucan to prevent shipping fever in imported heifers.
Pedroso M
Arch Med Res; 1994; 25(2):181. PubMed ID: 7919809
[TBL] [Abstract][Full Text] [Related]
5. Anthrax-protective effects of yeast beta 1,3 glucans.
Kournikakis B; Mandeville R; Brousseau P; Ostroff G
MedGenMed; 2003 Mar; 5(1):1. PubMed ID: 12827062
[TBL] [Abstract][Full Text] [Related]
6. Pro- and synbiotics to control inflammation and infection in patients with multiple injuries.
Giamarellos-Bourboulis EJ; Bengmark S; Kanellakopoulou K; Kotzampassi K
J Trauma; 2009 Oct; 67(4):815-21. PubMed ID: 19820590
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of an intraperitoneal antibiotic to reduce the incidence of infection in the trauma patient: a prospective, randomized study.
Yelon JA; Green JD; Evans JT
J Am Coll Surg; 1996 Jun; 182(6):509-14. PubMed ID: 8646351
[TBL] [Abstract][Full Text] [Related]
8. PGG-glucan, a leukocyte-specific immunostimulant, does not potentiate GVHD or allograft rejection.
Washburn WK; Otsu I; Gottschalk R; Monaco AP
J Surg Res; 1996 May; 62(2):179-83. PubMed ID: 8632636
[TBL] [Abstract][Full Text] [Related]
9. A phase II multicenter, double-blind, randomized, placebo-controlled study of three dosages of an immunomodulator (PGG-glucan) in high-risk surgical patients.
Babineau TJ; Hackford A; Kenler A; Bistrian B; Forse RA; Fairchild PG; Heard S; Keroack M; Caushaj P; Benotti P
Arch Surg; 1994 Nov; 129(11):1204-10. PubMed ID: 7979954
[TBL] [Abstract][Full Text] [Related]
10. Fluconazole improves survival in septic shock: a randomized double-blind prospective study.
Jacobs S; Price Evans DA; Tariq M; Al Omar NF
Crit Care Med; 2003 Jul; 31(7):1938-46. PubMed ID: 12847386
[TBL] [Abstract][Full Text] [Related]
11. Effect of PGG-glucan on the rate of serious postoperative infection or death observed after high-risk gastrointestinal operations. Betafectin Gastrointestinal Study Group.
Dellinger EP; Babineau TJ; Bleicher P; Kaiser AB; Seibert GB; Postier RG; Vogel SB; Norman J; Kaufman D; Galandiuk S; Condon RE
Arch Surg; 1999 Sep; 134(9):977-83. PubMed ID: 10487593
[TBL] [Abstract][Full Text] [Related]
12. Randomized phase I/II trial of a macrophage-specific immunomodulator (PGG-glucan) in high-risk surgical patients.
Babineau TJ; Marcello P; Swails W; Kenler A; Bistrian B; Forse RA
Ann Surg; 1994 Nov; 220(5):601-9. PubMed ID: 7979607
[TBL] [Abstract][Full Text] [Related]
13. Systemic inflammatory response syndrome and nosocomial infection in trauma.
Hoover L; Bochicchio GV; Napolitano LM; Joshi M; Bochicchio K; Meyer W; Scalea TM
J Trauma; 2006 Aug; 61(2):310-6; discussion 316-7. PubMed ID: 16917443
[TBL] [Abstract][Full Text] [Related]
14. Nosocomial infections in the surgical intensive care unit: a difference between trauma and surgical patients.
Wallace WC; Cinat M; Gornick WB; Lekawa ME; Wilson SE
Am Surg; 1999 Oct; 65(10):987-90. PubMed ID: 10515549
[TBL] [Abstract][Full Text] [Related]
15. The analysis of risk factors of impacting mortality rate in severe multiple trauma patients with posttraumatic acute respiratory distress syndrome.
Wu J; Sheng L; Ma Y; Gu J; Zhang M; Gan J; Xu S; Jiang G
Am J Emerg Med; 2008 May; 26(4):419-24. PubMed ID: 18410809
[TBL] [Abstract][Full Text] [Related]
16. Effects after inhalation of (1-->3)-beta-D-glucan and relation to mould exposure in the home.
Beijer L; Thorn J; Rylander R
Mediators Inflamm; 2002 Jun; 11(3):149-53. PubMed ID: 12137243
[TBL] [Abstract][Full Text] [Related]
17. Effects of glucan treatment on the Th1/Th2 balance in patients with allergic rhinitis: a double-blind placebo-controlled study.
Kirmaz C; Bayrak P; Yilmaz O; Yuksel H
Eur Cytokine Netw; 2005 Jun; 16(2):128-34. PubMed ID: 15941684
[TBL] [Abstract][Full Text] [Related]
18. Glucan-induced keratoderma in acquired immunodeficiency syndrome.
Duvic M; Reisman M; Finley V; Rapini R; DiLuzio NR; Mansell PW
Arch Dermatol; 1987 Jun; 123(6):751-6. PubMed ID: 2953313
[TBL] [Abstract][Full Text] [Related]
19. [Nosocomial infections in internal medicine departments].
Zamir D; Polychuck I; Leibovitz I; Reitblat T; Zamir C; Scharf S
Harefuah; 2003 Apr; 142(4):265-8, 318. PubMed ID: 12754875
[TBL] [Abstract][Full Text] [Related]
20. Short antibiotic prophylaxis for bacterial infections in a neonatal intensive care unit: a randomized controlled trial.
Auriti C; Ravà L; Di Ciommo V; Ronchetti MP; Orzalesi M
J Hosp Infect; 2005 Apr; 59(4):292-8. PubMed ID: 15749316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
